MedTrace Logo

Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors

NCT04958434 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2023-10-23

No results posted yet for this study

Summary

This is an open label Phase 1, first-in-human (FIH) study of TST005, a bi-specific antibody consisting of a PD-L1 monoclonal antibody (mAb) and a transforming growth factor beta (TGF-β) trap in subjects with locally advanced or metastatic cancers

Conditions

  • Locally Advanced or Metastatic Cancers
  • Metastatic Human Papillomavirus-Related Malignant Neoplasm

Interventions

DRUG

TST005

TST005 is a bifunctional human immunoglobulin G1 (IgG1) monoclonal

Sponsors & Collaborators

  • Suzhou Transcenta Therapeutics Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Charlie Qi, MD · Suzhou Transcenta Therapeutics Co., Ltd.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-11
Primary Completion
2023-09-30
Completion
2023-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04958434 on ClinicalTrials.gov